A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Summary

Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.

Timeline

Start

2021-01-12

Primary completion

2025-03-31

Completion

2025-10-21

Outcome

Outcome not reported

Stopped: “The study was stopped due to futility as per protocol”

Drugs

Indications